The recent announcement that a former president of the United States developed late-stage prostate cancer is a distressing reminder of the vulnerabilities present within the American healthcare
Phase 1b expansion study initiated in taxane-naïve mCRPC patients Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying
Telix Pharmaceuticals Limited announces that its prostate cancer PET imaging agent Illuccix has been granted marketing authorization by Fimea for the detection and localization of prostate-specific membrane
Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike. Lynx Dx, a leader in innovative diagnostic solutions, announces the publication
Owkin, a pioneer in Agentic AI for decoding the complexities of biology, has launched a comprehensive multimodal patient data discovery program to accelerate multimodal data
This December, Mount Sinai Hospital Department of Urology, under the leadership of Ash Tewari, MBBS, MCh, FRCS (Hon.), DSc (Hon.), System Chair of Urology at Mount
Fuel up with free Health Tech Insights
